BACKGROUND:Levosimendan is a promising new inodilator agent but its effectiveness in peripartum cardiomyopathy (PPCM) has not been tested in a clinical trial. The authors sought to evaluate the effect of levosimendan therapy and to determine the predictors of clinical outcome in patients with PPCM. METHODS AND RESULTS: The authors prospectively randomized 24 consecutive women with PPCM. Twelve patients (control group) were randomized to conventional heart failure therapy and 12 patients (levosimendan group) were randomized to levosimendan in addition to the conventional therapy. Mean follow-up period was 20.9 ± 9 months (ranged 12-38 months). The two groups did not differ in baseline demographic and echocardiographic characteristics. Eleven patients (45.8%) recovered completely (6 in control group and 5 in levosimendan group, p > 0.05), 6 died (25%) (3 in control group and 3 in levosimendan group), and 7 (29.1%) were left with persistent left ventricular dysfunction (PLVD) (3 in control group and 4 in levosimendan group, p > 0.05). There were significant differences in baseline characteristics between deceased patients and survivors including left ventricular end-diastolic diameter (7.1 ± 0.6 vs. 6.4 ± 0.5 cm, p = 0.031), left ventricular end-systolic diameter (LVESD) (6.4 ± 0.8 vs. 5.5 ± 0.6 cm, p = 0.027), left ventricular ejection fraction (LVEF) (19.7 vs. 27.4%, p = 0.025), and left atrial diameter (4.9 ± 0.3 vs. 4.3 ± 0.4 cm, p = 0.011). CONCLUSIONS: Addition of levosimendan to conventional therapy did not improve outcome in patients with PPCM. In patients with PLVD or patients who died, LVEF, LVESD and left atrial diameter were worse than those with complete resolution.
RCT Entities:
BACKGROUND:Levosimendan is a promising new inodilator agent but its effectiveness in peripartum cardiomyopathy (PPCM) has not been tested in a clinical trial. The authors sought to evaluate the effect of levosimendan therapy and to determine the predictors of clinical outcome in patients with PPCM. METHODS AND RESULTS: The authors prospectively randomized 24 consecutive women with PPCM. Twelve patients (control group) were randomized to conventional heart failure therapy and 12 patients (levosimendan group) were randomized to levosimendan in addition to the conventional therapy. Mean follow-up period was 20.9 ± 9 months (ranged 12-38 months). The two groups did not differ in baseline demographic and echocardiographic characteristics. Eleven patients (45.8%) recovered completely (6 in control group and 5 in levosimendan group, p > 0.05), 6 died (25%) (3 in control group and 3 in levosimendan group), and 7 (29.1%) were left with persistent left ventricular dysfunction (PLVD) (3 in control group and 4 in levosimendan group, p > 0.05). There were significant differences in baseline characteristics between deceased patients and survivors including left ventricular end-diastolic diameter (7.1 ± 0.6 vs. 6.4 ± 0.5 cm, p = 0.031), left ventricular end-systolic diameter (LVESD) (6.4 ± 0.8 vs. 5.5 ± 0.6 cm, p = 0.027), left ventricular ejection fraction (LVEF) (19.7 vs. 27.4%, p = 0.025), and left atrial diameter (4.9 ± 0.3 vs. 4.3 ± 0.4 cm, p = 0.011). CONCLUSIONS: Addition of levosimendan to conventional therapy did not improve outcome in patients with PPCM. In patients with PLVD or patients who died, LVEF, LVESD and left atrial diameter were worse than those with complete resolution.
Authors: B Bozkurt; F S Villaneuva; R Holubkov; T Tokarczyk; R J Alvarez; G A MacGowan; S Murali; W D Rosenblum; A M Feldman; D M McNamara Journal: J Am Coll Cardiol Date: 1999-07 Impact factor: 24.094
Authors: Karen Sliwa; Lori Blauwet; Kemi Tibazarwa; Elena Libhaber; Jan-Peter Smedema; Anthony Becker; John McMurray; Hatice Yamac; Saida Labidi; Ingrid Struman; Ingrid Struhman; Denise Hilfiker-Kleiner Journal: Circulation Date: 2010-03-22 Impact factor: 29.690
Authors: V S Moiseyev; P Põder; N Andrejevs; M Y Ruda; A P Golikov; L B Lazebnik; Z D Kobalava; L A Lehtonen; T Laine; M S Nieminen; K I Lie Journal: Eur Heart J Date: 2002-09 Impact factor: 29.983
Authors: Denise Hilfiker-Kleiner; Karol Kaminski; Edith Podewski; Tomasz Bonda; Arnd Schaefer; Karen Sliwa; Olaf Forster; Anja Quint; Ulf Landmesser; Carola Doerries; Maren Luchtefeld; Valeria Poli; Michael D Schneider; Jean-Luc Balligand; Fanny Desjardins; Aftab Ansari; Ingrid Struman; Ngoc Q N Nguyen; Nils H Zschemisch; Gunnar Klein; Gerd Heusch; Rainer Schulz; Andres Hilfiker; Helmut Drexler Journal: Cell Date: 2007-02-09 Impact factor: 41.582
Authors: F Follath; J G F Cleland; H Just; J G Y Papp; H Scholz; K Peuhkurinen; V P Harjola; V Mitrovic; M Abdalla; E-P Sandell; L Lehtonen Journal: Lancet Date: 2002-07-20 Impact factor: 79.321
Authors: J B O'Connell; M R Costanzo-Nordin; R Subramanian; J A Robinson; D E Wallis; P J Scanlon; R M Gunnar Journal: J Am Coll Cardiol Date: 1986-07 Impact factor: 24.094
Authors: Geert Koster; Jørn Wetterslev; Christian Gluud; Jan G Zijlstra; Thomas W L Scheeren; Iwan C C van der Horst; Frederik Keus Journal: Intensive Care Med Date: 2014-12-18 Impact factor: 17.440
Authors: B Löser; S Tank; G Hillebrand; B Goldmann; W Diehl; D Biermann; J Schirmer; D A Reuter Journal: Anaesthesist Date: 2013-05 Impact factor: 1.041
Authors: Victor H Nieto Estrada; Daniel L Molano Franco; Albert Alexander Valencia Moreno; Jose A Rojas Gambasica; Yamil E Jaller Bornacelli; Anacaona Martinez Del Valle Journal: J Clin Med Res Date: 2015-10-23